Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Min-Hee Ryu 14 Articles
General
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma
Cancer Res Treat. 2024;56(3):743-750.   Published online January 18, 2024
DOI: https://doi.org/10.4143/crt.2023.980
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
Materials and Methods
In this open-label, single-arm, dose-escalating, multicenter three-part phase 1/2a trial, patients had advanced solid tumors refractory to conventional therapy. Part 1 evaluated the safety and pharmacokinetics of five ascending once-daily doses of rivoceranib from 81 mg to 685 mg. Part 2 evaluated the safety and antitumor activity of once-daily rivoceranib 685 mg. Part 3 was conducted later, due to lack of maximum tolerated dose determination in part 1, to evaluate the safety and preliminary efficacy of once-daily rivoceranib 805 mg in patients with unresectable or advanced gastric cancer.
Results
A total of 61 patients were enrolled in parts 1 (n=25), 2 (n=30), and 3 (n=6). In parts 1 and 2, patients were white (45.5%) or Asian (54.5%), and 65.6% were male. The most common grade ≥ 3 adverse events were hypertension (32.7%), hyponatremia (10.9%), and hypophosphatemia (10.9%). The objective response rate (ORR) was 15.2%. In part 3, dose-limiting toxicities occurred in two out of six patients: grade 3 febrile neutropenia decreased appetite, and fatigue. The ORR was 33%.
Conclusion
The recommended phase 2 dose of rivoceranib was determined to be 685 mg once daily, which showed adequate efficacy with a manageable safety profile (NCT01497704 and NCT02711969).
  • 3,267 View
  • 130 Download
Close layer
Gastrointestinal cancer
GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment
Jaewon Hyung, Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Meesun Moon, Yoon-Koo Kang
Cancer Res Treat. 2024;56(1):199-207.   Published online June 20, 2023
DOI: https://doi.org/10.4143/crt.2023.490
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Heterogeneous human epidermal growth factor receptor 2 (HER2) overexpression in gastric cancer may lead to a misdiagnosis of HER2 status. Accurate assessment of HER2 status is essential for optimal treatment as novel HER2-directed agents are being investigated in various clinical settings. We evaluated the usefulness of HER2 re-assessment following progression on first-line treatment in initially HER2-negative advanced gastric cancer (AGC) patients.
Materials and Methods
We enrolled 177 patients with baseline HER2-negative AGC and performed HER2 re-assessment after progression on first-line treatment from February 2012 to June 2016 at Asan Medical Center, Seoul, Korea. The re-assessed HER2 status was analyzed with baseline HER2 status and clinical characteristics.
Results
The median age was 54 years (range, 24 to 80 years), and 123 patients (69.5%) were men. Seven patients (4.0%) were HER2-positive on the re-assessment. Patients with baseline HER2 negativity confirmed by a single test (n=100) had a higher HER2-positive re-assessment rate compared to those who had repeated baseline testing (n=77) (5.0% vs. 2.6%). Among the patients with single baseline HER2 testing, the rate was higher in patients with baseline HER2 immunohistochemistry (IHC) 1+ compared to those with IHC 0 (13.4% vs. 3.6%).
Conclusion
Overall, 4.0% of patients with baseline HER2-negative AGC were HER2-positive on re-assessment, and the HER2-positive re-assessment rate was higher among patients who had a single test at baseline. HER2 re assessment may be considered for initially HER2-negative patients to determine their eligibility for HER2-directed therapy, particularly if their HER2 negativity was determined by a single test, especially if they had a single baseline HER2 IHC 1+ test.
  • 3,158 View
  • 191 Download
Close layer
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
Cancer Res Treat. 2023;55(4):1250-1260.   Published online May 25, 2023
DOI: https://doi.org/10.4143/crt.2023.333
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by  
  • A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
    Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
    Clinical and Translational Oncology.2024;[Epub]     CrossRef
  • 3,436 View
  • 288 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Cancer Res Treat. 2022;54(4):1167-1174.   Published online December 6, 2021
DOI: https://doi.org/10.4143/crt.2021.1040
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Three years of adjuvant imatinib is the standard treatment for resected gastrointestinal stromal tumors (GISTs) with rupture, but the recurrence rate is prominently high. We aimed to investigate the efficacy and safety of 5-year adjuvant imatinib compared with 3-year treatment in patients with a ruptured GIST following surgical resection.
Materials and Methods
A total of 51 patients were included in the analysis. The assessment of GIST rupture was based on Nishida’s classification. Twenty patients who were diagnosed before November 2013 were treated with 5 years of imatinib, and 31 patients who were diagnosed after November 2013 were treated with 3 years of imatinib. We retrospectively compared the clinical outcomes of the two groups.
Results
Baseline characteristics and the incidence of the adverse events were generally comparable between the two groups. During a median follow-up duration of 43.8 months and 104.2 months in the 3- and 5-year group, 8 and 9 patients had a disease recurrence, respectively. The 5-year group showed better recurrence-free survival (RFS) than the 3-year group. In multivariate analysis, low mitotic index was a significant independent favorable prognostic factor for RFS, while 5-year imatinib treatment was marginally associated with a favorable RFS.
Conclusion
Five years of adjuvant imatinib treatment in patients with ruptured GIST was associated with favorable survival outcomes with manageable toxicity profiles. Our findings warrant validation and confirmation in future studies.

Citations

Citations to this article as recorded by  
  • Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
    Heikki Joensuu, Annette Reichardt, Mikael Eriksson, Peter Hohenberger, Kjetil Boye, Silke Cameron, Lars H. Lindner, Philipp J. Jost, Sebastian Bauer, Jochen Schütte, Stefan Lindskog, Raija Kallio, Panu M. Jaakkola, Dorota Goplen, Eva Wardelmann, Peter Rei
    British Journal of Cancer.2024; 131(2): 299.     CrossRef
  • Two Decades of Gastrointestinal Stromal Tumor Management With First-Line Treatment: A Case Report
    Maria M Pereira, Elisabete Couto, Ali Shamseddine, Teresa Macedo
    Cureus.2024;[Epub]     CrossRef
  • Imatinib

    Reactions Weekly.2023; 1960(1): 224.     CrossRef
  • Clinical importance of tumor rupture in gastrointestinal stromal tumor
    Toshirou Nishida, Naoto Gotouda, Tsuyoshi Takahashi, Hui Cao
    Journal of Digestive Diseases.2023;[Epub]     CrossRef
  • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
    Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
    Cancers.2023; 15(16): 4081.     CrossRef
  • Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours
    Nadia Peparini
    World Journal of Gastrointestinal Surgery.2023; 15(8): 1559.     CrossRef
  • Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
    Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
    International Journal of Cancer.2022; 151(10): 1770.     CrossRef
  • Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features
    Fu-Hai Wang, Hua-Long Zheng, Jin-Tao Li, Ping Li, Chao-Hui Zheng, Qi-Yue Chen, Chang-Ming Huang, Jian-Wei Xie
    La radiologia medica.2022; 127(10): 1085.     CrossRef
  • Development and validation of a prognostic model to predict the prognosis of patients with colorectal gastrointestinal stromal tumor: A large international population-based cohort study
    Yiding Li, Yujie Zhang, Yang Fu, Wanli Yang, Xiaoqian Wang, Lili Duan, Liaoran Niu, Junfeng Chen, Wei Zhou, Jinqiang Liu, Jing Wang, Daiming Fan, Liu Hong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 5,138 View
  • 199 Download
  • 5 Web of Science
  • 9 Crossref
Close layer
Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting
Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Heejung Chae, Eo Jin Kim, Mee-Sun Moon, Yoon-Koo Kang
Cancer Res Treat. 2021;53(2):436-444.   Published online October 6, 2020
DOI: https://doi.org/10.4143/crt.2020.725
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy patterns.
Materials and Methods
A total of 5,384 patients who received chemotherapy for MRGC between 2000 and 2015 were analyzed. The analysis focused on a comparison of the first-line chemotherapy between four periods: 2000–2003 (period 1), 2004–2007 (period 2), 2008–2011 (period 3), and 2012–2015 (period 4).
Results
There were 880 patients (16%) in period 1, 1,573 (29%) in period 2, 1,435 (27%) in period 3, and 1,496 (28%) in period 4. Cytotoxic doublet-based therapy was the most commonly used (78%) first-line chemotherapy, and the combination of trastuzumab and doublet chemotherapy was provided to 288 patients. The OS rates at 12 and 24 months were steadily improved as follows: 39.2% and 14.6% in period 1, 43.5% and 17.6% in period 2, 50.3% and 20.6% in period 3, and 51.7% and 24.1% in period 4, respectively (p < 0.001). Among the patients who received the doublet-based chemotherapy, the median OS of those who received trastuzumab was 18.0 months (95% CI, 15.5–20.6), while that of those who received other doublet therapies was 11.2 months (95% CI, 10.8–11.6).
Conclusion
The OS was improved over time with advancements in chemotherapy, particularly the introduction of the anti-HER2–targeted agent, which contributed to the increase in the number of long-term survivors and established the superiority of OS for the treatment of MRGC.

Citations

Citations to this article as recorded by  
  • Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair
    Young-Gyu Park, Hyung-Don Kim, Jaewon Hyung, Young Soo Park, Min-Hee Ryu
    Gastric Cancer.2024; 27(4): 840.     CrossRef
  • Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
    Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2024; 56(4): 1136.     CrossRef
  • Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination
    Sun Young Rha, Hyun Cheol Chung
    Journal of Gastric Cancer.2023;[Epub]     CrossRef
  • Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Yangsoon Park, Meesun Moon, Hyungeun Lee, Yoon-Koo Kang
    Gastric Cancer.2022; 25(4): 794.     CrossRef
  • Clinicopathological features and CT findings of papillary gastric adenocarcinoma
    Mengying Xu, Song Liu, Xiangmei Qiao, Lin Li, Changfeng Ji, Zhengyang Zhou
    Abdominal Radiology.2022; 47(11): 3698.     CrossRef
  • New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
    Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Mee-Sun Moon, Yoon-Koo Kang
    World Journal of Gastroenterology.2021; 27(48): 8357.     CrossRef
  • 6,315 View
  • 162 Download
  • 6 Crossref
Close layer
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
Jwa Hoon Kim, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Kyu-pyo Kim, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Jihun Kim, Sun-Ju Byeon, Yoon-Koo Kang
Cancer Res Treat. 2018;50(2):518-529.   Published online May 24, 2017
DOI: https://doi.org/10.4143/crt.2017.005
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the efficacy and safety of induction chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic gastric cancer (GC).
Materials and Methods
Patients with LAGC or unresectable PAN metastatic GC received six induction chemotherapy cycles (60 mg/m2 docetaxel intravenously on day 1, 937.5 mg/m2 capecitabine orally twice daily on days 1-14, 60 mg/m2 cisplatin intravenously on day 1, and 7.5 mg/kg BEV intravenously on day 1 every 3 weeks), followed by conversion surgery. The primary endpoint was R0 resection rate.
Results
Thirty-one patients with invasion to adjacent organs but without PAN metastasis (n=14, LAGC group) or with PAN metastasis regardless of invasion (n=17, PAN group) were enrolled between July 2010 and December 2014. Twenty-seven patients (87.1%) completed six chemotherapy cycles. The most common grade ≥ 3 toxicities were neutropenia (71%), neutropenia with fever/infection (22.6%/3.2%), and stomatitis (16.1%). The clinical response and R0 resection rates were 64.3% (95% confidence interval [CI], 46.6 to 82.0) and 64.5% (LAGC group, 71.4%; PAN group, 58.8%), respectively. The pathological complete regression rate was 12.9%. After a median follow-up of 44.5 months (range, 39.4 to 49.7 months), the median progression-free survival and overall survival were 13.1 months (95% CI, 8.9 to 17.3) and 38.6 months (95% CI, 22.0 to 55.1), respectively.
Conclusion
Induction chemotherapy with DXP+BEV displayed antitumor activities with encouraging R0 resection rate and manageable toxicity profiles on patients with LAGC or PAN metastatic GC.

Citations

Citations to this article as recorded by  
  • Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
    Liang Wang, Wei Li, Ya-Gang Liu, Cui Zhang, Wei-Na Gao, Li-Fei Gao, Wei long Zhong
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
    Deguo Yu, Zhenfeng Wang, Tingbang He, Lijun Yang
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Research progress in targeted therapy and immunotherapy for gastric cancer
    Xuewei Li, Jun Xu, Jun Xie, Wenhui Yang
    Chinese Medical Journal.2022; 135(11): 1299.     CrossRef
  • Novel Drug Delivery Method Targeting Para-Aortic Lymph Nodes by Retrograde Infusion of Paclitaxel into Pigs’ Thoracic Duct
    Akira Saito, Natsuka Kimura, Yuji Kaneda, Hideyuki Ohzawa, Hideyo Miyato, Hironori Yamaguchi, Alan Kawarai Lefor, Ryozo Nagai, Naohiro Sata, Joji Kitayama, Kenichi Aizawa
    Cancers.2022; 14(15): 3753.     CrossRef
  • New therapeutic options opened by the molecular classification of gastric cancer
    Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu
    World Journal of Gastroenterology.2018; 24(18): 1942.     CrossRef
  • Gastric cancer: Basic aspects
    Henrique O. Duarte, Joana Gomes, José C. Machado, Celso A. Reis
    Helicobacter.2018;[Epub]     CrossRef
  • 9,032 View
  • 312 Download
  • 11 Web of Science
  • 6 Crossref
Close layer
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Res Treat. 2017;49(4):851-868.   Published online January 3, 2017
DOI: https://doi.org/10.4143/crt.2016.176
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis
    Liang Wang, Juyuan Li, Huamin Chen
    Chemotherapy.2024; 69(1): 11.     CrossRef
  • Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
    Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, Anidrisha Sahu, Darin M. Mathkor, Shafiul Haque, Deepika Raina, Seema Ramniwas, Madhu Gupta, Hardeep S. Tuli
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
    Huina Wang, Qingzhu Ding, Haihua zhou, Chuanjiang Huang, Guiyuan Liu, Xiaojun Zhao, Zhiyi Cheng, Xiaolan You
    Phytomedicine.2024; 134: 155962.     CrossRef
  • Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
    Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
    Cancer Medicine.2023; 12(7): 7784.     CrossRef
  • Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
    Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510
    Anica Högner, Salah‐Eddin Al‐Batran, Jens T. Siveke, Mario Lorenz, Prisca Bartels, Kirstin Breithaupt, Peter Malfertheiner, Nils Homann, Alexander Stein, Dietrich Gläser, Ingo Tamm, Axel Hinke, Arndt Vogel, Peter Thuss‐Patience
    International Journal of Cancer.2022; 150(6): 1007.     CrossRef
  • Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
    Linyan Zhang, Simeng Qin, Liuyi Lu, Li Huang, Shan Li
    The International Journal of Biological Markers.2022; 37(1): 66.     CrossRef
  • Tumor vessel normalization and immunotherapy in gastric cancer
    Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
    Yanling Ai, Ziyi Zhao, Hengyi Wang, Xiaomei Zhang, Weihan Qin, Yanlei Guo, Maoyuan Zhao, Jianyuan Tang, Xiao Ma, Jinhao Zeng
    Phytotherapy Research.2022; 36(9): 3371.     CrossRef
  • Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
    Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
    RSC Advances.2022; 12(34): 21821.     CrossRef
  • Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, Renuka Coudhary, Diwakar Aggarwal, Manoj Kumar, Ujjawal Sharma, Nidarshana Chaturvedi Parashar, Shafiul Haque, Katrin Sak
    Molecules.2022; 27(21): 7653.     CrossRef
  • Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis
    Yanjun Mi, Yongwen Li, Zhuo He, Donghan Chen, Qingqi Hong, Jun You
    Cancer Management and Research.2021; Volume 13: 899.     CrossRef
  • Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
    Shucheng Chen, Lan Yao
    Cancer Chemotherapy and Pharmacology.2021; 88(2): 323.     CrossRef
  • Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC
    Yuanyuan Ma, Xinyu Su, Xin Li, Xiaohui Zhi, Kan Jiang, Jianhong Xia, Hongliang Li, Chen Yan, Liqing Zhou
    Scientific Reports.2021;[Epub]     CrossRef
  • Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
    Xing Kang, En Xu, Xingzhou Wang, Lulu Qian, Zhi Yang, Heng Yu, Chao Wang, Chuanfu Ren, Yizhou Wang, Xiaofeng Lu, Xuefeng Xia, Wenxian Guan, Tong Qiao
    Cell Death & Disease.2021;[Epub]     CrossRef
  • A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
    Lin Li, Yuexian Li, Huawei Zou
    PeerJ.2021; 9: e12356.     CrossRef
  • Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hi
    Journal of Gastroenterology.2020; 55(6): 627.     CrossRef
  • The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
    Shahrzad S. Fard, Kioomars Saliminejad, Masoud Sotoudeh, Niloofar Soleimanifard, Shaghayegh Kouchaki, Mansour Yazdanbod, Habibollah Mahmoodzadeh, Ardeshir Ghavamzadeh, Reza Malekzadeh, Bahram Chahardouli, Kamran Alimoghaddam, Seyed H. Ghaffari
    Anti-Cancer Agents in Medicinal Chemistry.2020; 19(17): 2097.     CrossRef
  • Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, Ilaria Maggio, Maria Massucci, Fabiola Lorena Rojas Limpe, Francesca Di Fabio, Andrea Ardizzoni
    Future Oncology.2020; 16(2): 4409.     CrossRef
  • S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
    Chu Zhang, Guang-Mao Yu, Miao Zhang, Dong Liu
    Medicine.2020; 99(1): e18691.     CrossRef
  • An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
    Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianf
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
    Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun
    International Journal of Clinical Oncology.2020; 25(6): 1195.     CrossRef
  • Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He, Mingyan E
    Expert Review of Clinical Pharmacology.2020; 13(12): 1423.     CrossRef
  • Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
    Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
    Journal of Gastrointestinal Cancer.2019; 50(3): 556.     CrossRef
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
    Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai
    Journal of Gastrointestinal Cancer.2019; 50(4): 943.     CrossRef
  • Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
    Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
    Drug Safety.2019; 42(2): 159.     CrossRef
  • VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
    Lian Lian, Xiang-Li Li, Meng-Dan Xu, Xian-Min Li, Meng-Yao Wu, Yan Zhang, Min Tao, Wei Li, Xiao-Ming Shen, Chong Zhou, Min Jiang
    BMC Cancer.2019;[Epub]     CrossRef
  • STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB
    O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko
    Research and Practical Medicine Journal.2019; 6(3): 20.     CrossRef
  • Tumor progression-dependent angiogenesis in gastric cancer and its potential application
    Hsi-Lung Hsieh, Ming-Ming Tsai
    World Journal of Gastrointestinal Oncology.2019; 11(9): 686.     CrossRef
  • Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
    Guohui Liu, Chunbo Wang, Yunlong He, Mingyan E
    BMC Pharmacology and Toxicology.2019;[Epub]     CrossRef
  • N-methyl-N-nitro-N-nitrosoguanidine-mediated ING4 downregulation contributed to the angiogenesis of transformed human gastric epithelial cells
    Yansu Chen, Rui Fu, Mengdie Xu, Yefei Huang, Guixiang Sun, Lichun Xu
    Life Sciences.2018; 199: 179.     CrossRef
  • GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
    Keshuo Ding, Sheng Tan, Xing Huang, Xiaonan Wang, Xiaocan Li, Rong Fan, Yong Zhu, Peter E. Lobie, Wenbin Wang, Zhengsheng Wu
    Journal of Biological Chemistry.2018; 293(11): 3949.     CrossRef
  • Nanoparticles designed to regulate tumor microenvironment for cancer therapy
    Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou, Wei Wang
    Life Sciences.2018; 201: 37.     CrossRef
  • Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
    Xiaodong Wang, Yu Liu, Yuwen Diao, Ningning Gao, Yanyan Wan, Jingjing Zhong, Huali Zheng, Zhulin Wang, Guangyi Jin
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer
    In-Hwan Kim
    Annals of Surgical Oncology.2018; 25(S3): 749.     CrossRef
  • Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
    Mingzhe Lin, Xin Li, Haizhou Guo, Faxiang Ji, Linhan Ye, Xuemei Ma, Wen Cheng
    Current Bioinformatics.2018; 14(1): 62.     CrossRef
  • Antiangiogenic effects of oridonin
    Lili Tian, Kangjie Xie, Donglai Sheng, Xiaoqing Wan, Guofu Zhu
    BMC Complementary and Alternative Medicine.2017;[Epub]     CrossRef
  • The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
    Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad A. M. Al Mazeedi, Hashim A. M. Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S. Pepper, M. Iqbal Parker, Kevin Dzobo
    International Journal of Molecular Sciences.2017; 18(7): 1586.     CrossRef
  • Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
    Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
    Scientific Reports.2017;[Epub]     CrossRef
  • Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
    Henrik Nienhüser, Thomas Schmidt
    International Journal of Molecular Sciences.2017; 19(1): 43.     CrossRef
  • 17,004 View
  • 922 Download
  • 45 Web of Science
  • 40 Crossref
Close layer
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang
Cancer Res Treat. 2017;49(2):350-357.   Published online July 19, 2016
DOI: https://doi.org/10.4143/crt.2016.067
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients.
Materials and Methods
Fifty-seven Korean patientswith advanced GISTwho experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off).
Results
None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for ≥ 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31).
Conclusion
This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.

Citations

Citations to this article as recorded by  
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
    Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
    International Journal of Clinical Oncology.2024; 29(6): 647.     CrossRef
  • A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
    British Journal of Cancer.2023; 129(2): 275.     CrossRef
  • Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
    Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
    Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
    Cancers.2023; 15(16): 4081.     CrossRef
  • Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review
    Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen
    Critical Reviews in Oncology/Hematology.2022; 172: 103650.     CrossRef
  • Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
    Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson
    Cancers.2022; 14(7): 1832.     CrossRef
  • Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors
    Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
    International Journal of Clinical Oncology.2022; 27(7): 1164.     CrossRef
  • The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
    Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee, Raga Sruthi Dwarampudi, Sheena Mathew, Sumahitha Bichenapally, Lubna Mohammed
    Cureus.2022;[Epub]     CrossRef
  • CT Image Examination Based on Virtual Reality Analysis in Clinical Diagnosis of Gastrointestinal Stromal Tumors
    Zhiying Wang, Qiaoyan Qu, Ke Cai, Ting Xu, Zhihan Lv
    Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
  • The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
    Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska
    International Journal of Molecular Sciences.2021; 22(21): 12089.     CrossRef
  • Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors
    Seketoulie Keretsu, Suparna Ghosh, Seung Joo Cho
    International Journal of Molecular Sciences.2020; 21(21): 8232.     CrossRef
  • Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study
    Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh
    Oncology Letters.2020; 20(3): 2131.     CrossRef
  • Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers
    Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li, Houjie Liang
    Advances in Therapy.2019; 36(8): 1986.     CrossRef
  • Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
    Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
    The Oncologist.2019; 24(11): e1212.     CrossRef
  • Growing Role of Regorafenib in the Treatment of Patients with Sarcoma
    Mark Agulnik, Steven Attia
    Targeted Oncology.2018; 13(4): 417.     CrossRef
  • Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
    Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Ne
    Scientific Reports.2017;[Epub]     CrossRef
  • Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
    Bin Zhao, Hong Zhao
    Oncotarget.2017; 8(55): 93813.     CrossRef
  • 10,145 View
  • 371 Download
  • 22 Web of Science
  • 17 Crossref
Close layer
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Res Treat. 2016;48(4):1155-1166.   Published online June 24, 2016
DOI: https://doi.org/10.4143/crt.2016.187
AbstractAbstract PDFPubReaderePub
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.

Citations

Citations to this article as recorded by  
  • Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis
    Chunhui Shou, Zhou Chen, Zhijian Li, Weili Yang, Qing Zhang, Hao Bai, Jiren Yu
    Scandinavian Journal of Gastroenterology.2024; 59(2): 239.     CrossRef
  • Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors
    Toshihiko Doi, Noboru Yamamoto, Shuichi Ohkubo
    Future Oncology.2024; 20(9): 507.     CrossRef
  • Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China
    Zhengting He, Chen Du, Bingqian Cheng, Jiancong Feng, Nanjun Wang, Yan Ma, Longsong Li, Bo Zhang, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
    Surgical Endoscopy.2024; 38(3): 1398.     CrossRef
  • Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors
    Jing-wen Zhang, Chang-qing Guo, Shan-shan Zhu, Ghulam Nabi, Nan Dai, Xiao-yu Wan, Ping Liu, Fang-bin Zhang, Yang Fu, Xin-gung Cao
    Digestive Diseases and Sciences.2024; 69(5): 1755.     CrossRef
  • Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images
    Mingyan Cai, Baohui Song, Yinhui Deng, Pingting Gao, Shilun Cai, Ayimukedisi Yalikong, Enpan Xu, Yunshi Zhong, Jinhua Yu, Pinghong Zhou
    Gastrointestinal Endoscopy.2024; 99(4): 537.     CrossRef
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
    Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
    International Journal of Clinical Oncology.2024; 29(6): 647.     CrossRef
  • Efficacy and Safety of Endoscopic Resection for Gastric Gastrointestinal Stromal Tumors Originating from the Muscularis Propria
    Ji Li, Dong Xu, Wei-Feng Huang, Shao-Kun Hong, Jin-Yan Zhang
    Digestive Diseases and Sciences.2024; 69(6): 2184.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study
    Enpan Xu, Qiang Shi, Zhipeng Qi, Bing Li, Huihui Sun, Zhong Ren, Shilun Cai, Dongli He, Zhengtao Lv, Zhanghan Chen, Liang Zhong, Leiming Xu, Xiaobo Li, Shuchang Xu, Pinghong Zhou, Yunshi Zhong
    Surgical Endoscopy.2024; 38(6): 3353.     CrossRef
  • Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative)
    Johnn Henry Herrera Kok, Luigi Marano, Jan Willem van den Berg, Preethi Shetty, Yogesh Vashist, Laura Lorenzon, Beate Rau, Richard van Hillegersberg, Giovanni de Manzoni, Andrea Spallanzani, Won Jun Seo, Hiromi Nagata, Clarisse Eveno, Stefan Mönig, Karen
    European Journal of Surgical Oncology.2024; 50(7): 108387.     CrossRef
  • Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study
    Zhixia Dong, Xiangyun Zhao, Hangbin Zheng, HanYao Zheng, Dafan Chen, Jia Cao, Zili Xiao, Yunwei Sun, Qian Zhuang, Shan Wu, Jie Xia, Min Ning, Binjie Qin, Hui Zhou, Jinsong Bao, Xinjian Wan
    eClinicalMedicine.2024; 73: 102656.     CrossRef
  • Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
    Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Changhoon Yoo, Sung-Joo Kim, Yoon-Koo Kang
    Clinical Cancer Research.2024; 30(13): 2743.     CrossRef
  • Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST)
    Shanshan Zhu, Changqing Guo, Jingwen Zhang, Nan Dai, Saif Ullah, Ping Liu, Yang Fu, Ge Zhang, Fangbin Zhang, Shengang Zhang, Xinguang Cao
    European Journal of Surgical Oncology.2024; 50(9): 108527.     CrossRef
  • Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors
    Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Sh
    BJC Reports.2024;[Epub]     CrossRef
  • Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)
    Sejin Kim, Hyung-Don Kim, Eo Jin Kim, Min-Hee Ryu, Yoon-Koo Kang
    BMC Cancer.2024;[Epub]     CrossRef
  • Unraveling Gastric and Small Intestine Gastrointestinal Stromal Tumors: A Review of Our Current Knowledge
    Panagiotis Eskitzis, Vasiliki Michou, Rodoula Theoti, Antonia Antoniou, Drosos Tsavlis, Doxakis Anestakis
    Gastrointestinal Disorders.2024; 6(4): 842.     CrossRef
  • Mean platelet volume/platelet count ratio can predict the recurrence-free survival rate of patients after complete resection of gastrointestinal stromal tumors
    Xinlian Du, Xinxin Zang, Hanbo Zhang, Lijia Liu, Ying Xu, Xuedong Li, Ruishu Mou, Haitao Xu, Jiuxin Zhu, Rui Xie
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • Splenic capsulitis associated with gastric GIST
    Soumya Hariswamy, Sam Alhayo, Yasser Farooque
    ANZ Journal of Surgery.2023; 93(4): 1104.     CrossRef
  • Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications
    Michela Campora, Michele Paudice, Alessandro Gambella, Danila Comandini, Paola Parente, Marta Sbaraglia, Angelo Paolo Dei Tos, Federica Grillo, Luca Mastracci
    Virchows Archiv.2023; 482(3): 589.     CrossRef
  • Pure endoscopic resection versus laparoscopic assisted procedure for upper gastrointestinal stromal tumors: Perspective from a surgical endoscopist
    Hon Chi Yip, Jun Liang Teh, Anthony Y. B. Teoh, Philip Chiu
    Digestive Endoscopy.2023; 35(2): 184.     CrossRef
  • Gastrointestinal stromal tumor of jejunum misdiagnosed as uterine leiomyoma: A case report
    Min Yu, Miaomiao Sun, Shanwei Guo, Fangfang Nan
    Asian Journal of Surgery.2023; 46(3): 1457.     CrossRef
  • A Rare Gastric Subepithelial Lesion Removed through Submucosal Tunneling Endoscopic Resection: Case Report and Literature Review
    Mu-Ming Chien, Yun-Ho Lin, Chun-Chao Chang, Hsi-Yuan Chien
    Life.2023; 13(1): 179.     CrossRef
  • Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach
    Moon Kyung Joo, Jong-Jae Park, Yeon Ho Lee, Beom Jae Lee, Seong Min Kim, Won Shik Kim, Ah Young Yoo, Hoon Jai Chun, Sang Woo Lee
    Gut and Liver.2023; 17(2): 217.     CrossRef
  • Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
    Yoichi Naito, Toshirou Nishida, Toshihiko Doi
    Gastric Cancer.2023; 26(3): 339.     CrossRef
  • Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions
    Yoon-Koo Kang, Hyung-Don Kim, Hyun Jin Kim, Young Soo Park, Mo-Youl Beck, Min-Hee Ryu
    Gastric Cancer.2023; 26(4): 604.     CrossRef
  • Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study
    Muhan Ni, Dehua Tang, Wei Ren, Rui Meng, Jinping Yang, Peng Yan, Xiwei Ding, Guifang Xu, Ying Lv, Min Chen, Hua Yang, Lei Wang
    Gastric Cancer.2023; 26(4): 590.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China
    Jia-Xin Xu, Tian-Yin Chen, Yan-Bo Liu, Xiao-Yue Xu, Wei-Feng Chen, Quan-Lin Li, Jian-Wei Hu, Wen-Zheng Qin, Ming-Yan Cai, Yi-Qun Zhang, Ping-Hong Zhou
    Surgical Endoscopy.2023; 37(8): 5883.     CrossRef
  • Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis
    Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang
    Cancer Medicine.2023; 12(11): 12187.     CrossRef
  • A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
    British Journal of Cancer.2023; 129(2): 275.     CrossRef
  • Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China
    Chen Du, Zhengting He, Longsong Li, Bo Ning, Bo Zhang, Yaqi Zhai, Yan Ma, Ke Han, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102152.     CrossRef
  • Clinical importance of tumor rupture in gastrointestinal stromal tumor
    Toshirou Nishida, Naoto Gotouda, Tsuyoshi Takahashi, Hui Cao
    Journal of Digestive Diseases.2023;[Epub]     CrossRef
  • Gastrointestinal Stromal Tumor of Small Intestine
    Hyo Yeop Song, Geom Seog Seo, Hoon Gil Jo
    The Korean Journal of Gastroenterology.2023; 81(6): 276.     CrossRef
  • Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
    Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa
    Gastric Cancer.2023; 26(5): 775.     CrossRef
  • Non-exposed endoscopic wall-inversion surgery with one-step nucleic acid amplification for early gastrointestinal tumors: Personal experience and literature review
    Francesco Crafa, Serafino Vanella, Aristide Morante, Onofrio A Catalano, Kelsey L Pomykala, Mario Baiamonte, Maria Godas, Alexandra Antunes, Joaquim Costa Pereira, Valentina Giaccaglia
    World Journal of Gastroenterology.2023; 29(24): 3883.     CrossRef
  • Transgastric endoscopic ultrasound‐guided fine needle biopsy for diagnosing gastrointestinal stromal tumor of the jejunum
    Yuichi Takano, Fumitaka Niiya, Masatsugu Nagahama
    Digestive Endoscopy.2023;[Epub]     CrossRef
  • Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor
    Yating Wang, Genji Bai, Hui Zhang, Wei Chen
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors
    Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Hung-Chi Chang, Chew-Teng Kor, Szu-Chia Wu, Kuo-Hua Lin
    World Journal of Gastrointestinal Surgery.2023; 15(8): 1629.     CrossRef
  • Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors
    Ximei Ren, Muhan Ni, Tingting Zhu, Jinping Yang, Jinyan Liu, Shahzeb Hassan, Xiaoping Zou, Guifang Xu, Lei Wang
    Digestive Diseases.2023; 41(2): 187.     CrossRef
  • A giant gastric stromal tumor with dizziness as the main complaint: A case report and literature review
    Dongdong Zhang, Shuk Ying WONG, Jixiang Wu, Limin Guo
    International Journal of Surgery Case Reports.2023; 110: 108747.     CrossRef
  • Survival outcome of local versus radical resection for jejunoileal gastrointestinal stromal tumors: a propensity score-matched population-based analysis
    Shangcheng Yan, Wei Peng, Ming Cheng, Jingyu Zhang, Tianhua Liu, Mengchao Sheng, Rui Ren, Qiang Chen, Wei Gong, Yongyou Wu
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series
    Li-Jun Chen, Yue-Dong Han, Ming Zhang
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Rapidly Growing, High-Risk Gastrointestinal Stromal Tumor of the Stomach: A Case Report
    Sung Jin Lim, Han Mo Yoo, Seung-Woo Lee, Hae Joung Sul, Dong Soo Lee
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2023; 23(4): 306.     CrossRef
  • Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study
    Jia-Zheng Liu, Zhong-Wen Jia, Ling-Ling Sun
    World Journal of Radiology.2023; 15(12): 350.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of gastric gastrointestinal stromal tumors originating from the muscularis propria: a 7-year experience from a large tertiary center in China
    Chen Du, Ningli Chai, Enqiang Linghu, Huikai Li, Yaqi Zhai, Longsong Li, Xiaowei Tang, Hongbin Wang, Ping Tang
    Surgical Endoscopy.2022; 36(2): 1544.     CrossRef
  • Radiomics Nomogram Based on Contrast-enhanced CT to Predict the Malignant Potential of Gastrointestinal Stromal Tumor: A Two-center Study
    Yancheng Song, Jie Li, Hexiang Wang, Bo Liu, Chentong Yuan, Hao Liu, Ziwen Zheng, Fanyi Min, Yu Li
    Academic Radiology.2022; 29(6): 806.     CrossRef
  • Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors
    Keiko Maekawa, Masahiro Yamamura, Atsushi Matsuki, Takashi Ishikawa, Toshihiro Hirai, Yoshiyuki Yamaguchi, Yoshiro Saito, Tatsuo Kanda
    Drug Metabolism and Pharmacokinetics.2022; 43: 100441.     CrossRef
  • Clinical Course of Small Subepithelial Tumors of the Small Bowel Detected on CT
    Seohyun Kim, Seung Joon Choi, Su Joa Ahn, So Hyun Park, Young Sup Shim, Jeong Ho Kim
    Journal of the Korean Society of Radiology.2022; 83(3): 608.     CrossRef
  • Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China
    Deqiong Wang, Qiang Ding, Li Cao, Xinxia Feng, Zerui Zhang, Panpan Lu, Xiaoyu Ji, Lili Li, Dean Tian, Mei Liu
    Scandinavian Journal of Gastroenterology.2022; 57(8): 996.     CrossRef
  • The Diagnosis of Small Gastrointestinal Subepithelial Lesions by Endoscopic Ultrasound-Guided Fine Needle Aspiration and Biopsy
    Masanari Sekine, Takeharu Asano, Hirosato Mashima
    Diagnostics.2022; 12(4): 810.     CrossRef
  • A Huge Malignant Gastric Gastrointestinal Stromal Tumor in a Young Patient
    Yun Jin Jeong, Hyun Seung Hwang, Yong Eun Park, Kyung Han Nam, Sung Jin Oh
    The Korean Journal of Gastroenterology.2022; 79(4): 177.     CrossRef
  • Advancements in the Diagnosis of Gastric Subepithelial Tumors
    Osamu Goto, Mitsuru Kaise, Katsuhiko Iwakiri
    Gut and Liver.2022; 16(3): 321.     CrossRef
  • Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
    Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2022; 54(4): 1167.     CrossRef
  • The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection
    Hui Qu, ZhaoHui Xu, YanYing Ren, ZeZhong Gong, Ri Hyok Ju, Fan Zhang, Shuai Shao, XiaoLiang Chen, Xin Chen
    Medicine.2022; 101(25): e29487.     CrossRef
  • Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
    Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
    International Journal of Cancer.2022; 151(10): 1770.     CrossRef
  • Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study
    Zhou Zhao, Xiao-Nan Yin, Jian Wang, Xin Chen, Zhao-Lun Cai, Bo Zhang
    World Journal of Gastroenterology.2022; 28(27): 3476.     CrossRef
  • Therapeutic Effects of 4 Surgical Approaches for Small Gastrointestinal Stromal Tumors: A Network Meta-analysis
    Zhiyuan Yu, Huaiyu Tu, Chen Liang, Shuzhong Qiu, Xiaoyu Dong, Yonghui Zhang, Chao Ma, Peiyu Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022;[Epub]     CrossRef
  • Necessity of Individualized Approach for Gastric Subepithelial Tumor Considering Pathologic Discrepancy and Surgical Difficulty Depending on the Gastric Location
    Sung Gon Kim, Bang Wool Eom, Hongman Yoon, Myeong-Cheorl Kook, Young-Woo Kim, Keun Won Ryu
    Journal of Clinical Medicine.2022; 11(16): 4733.     CrossRef
  • Laparoscopic versus open resection for the treatment of gastric GIST: a retrospective 10-year single-center experience
    Andrea LOCATELLI, Daniele CARZANIGA, Pierluigi CARZANIGA, Andrea COSTANZI
    Minerva Surgery.2022;[Epub]     CrossRef
  • Case report: 10-year survival of a patient with a primary hepatic gastrointestinal stromal tumor
    Jie Lian, Meiyan Feng, Shumei Zhang, Haibo Lu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical outcomes of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor
    Hiroyuki Hanayama, Masanori Katagata, Takahiro Sato, Hiroshi Nakano, Takuro Matsumoto, Takeshi Tada, Yohei Watanabe, Suguru Hayase, Hirokazu Okayama, Tomoyuki Momma, Tsunetaka Kato, Minami Hashimoto, Jun Nakamura, Takuto Hikichi, Zenichiro Saze, Koji Kono
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE.2022; 68(3): 169.     CrossRef
  • Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
    Yuichi Ichinose, Yi-Hsin Yang, Hui-Jen Tsai, Ru-Yu Huang, Takahiro Higashi, Toshirou Nishida, Li-Tzong Chen
    Scientific Reports.2022;[Epub]     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine
    Bozhi Hu, Chao Wang, Kewei Jiang, Zhanlong Shen, Xiaodong Yang, Mujun Yin, Bin Liang, Qiwei Xie, Yingjiang Ye, Zhidong Gao
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population‐based study
    Lu Xu, Yanpeng Ma, Shengfeng Wang, Jingnan Feng, Lili Liu, Jinxi Wang, Guozhen Liu, Dianrong Xiu, Wei Fu, Siyan Zhan, Tao Sun, Pei Gao
    Cancer Medicine.2021; 10(2): 737.     CrossRef
  • Malignant solitary fibrous tumor of the greater omentum: A case report and review of literature
    Yu-Chen Guo, Li-Yu Yao, Zhi-Sen Tian, Bing Shi, Ying Liu, Yuan-Yi Wang
    World Journal of Clinical Cases.2021; 9(2): 445.     CrossRef
  • A Case of Liver Metastasis from Small Intestinal Gastrointestinal Stromal Tumor 25 Years after Surgery including Autopsy Findings
    Yuichi Takano, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Takahiro Kobayashi, Fumitaka Niiya, Eiichi Yamamura, Naotaka Maruoka, Kuniyo Gomi, Yuichiro Kuroki, Yorimasa Yamamoto, Tomoko Norose, Nobuyuki Ohike, Masatsugu Nagahama, Marcel Cerqueira Cesar Ma
    Case Reports in Gastrointestinal Medicine.2021; 2021: 1.     CrossRef
  • Gastrointestinal stromal tumours
    Jean-Yves Blay, Yoon-Koo Kang, Toshiroo Nishida, Margaret von Mehren
    Nature Reviews Disease Primers.2021;[Epub]     CrossRef
  • A modified endoscopic full thickness resection for gastric subepithelial tumors from muscularis propria layer: Novel method
    Jung Min Lee, In Kyung Yoo, Sung Pyo Hong, Joo Young Cho, Young Kwan Cho
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2558.     CrossRef
  • Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
    Toshirou Nishida, Shigetaka Yoshinaga, Tsuyoshi Takahashi, Yoichi Naito
    Cancers.2021; 13(13): 3158.     CrossRef
  • Diagnosis of gastric submucosal tumors and estimation of malignant risk of GIST by endoscopic ultrasound. Comparison between B mode and contrast-harmonic mode
    Christine Lefort, Vikas Gupta, Andrea Lisotti, Laurent Palazzo, Pietro Fusaroli, Bertrand Pujol, Rodica Gincul, Fabien Fumex, Maxime Palazzo, Bertrand Napoléon
    Digestive and Liver Disease.2021; 53(11): 1486.     CrossRef
  • Gastrointestinal Stromal Tumors—A Mini Review
    Gina Gheorghe, Nicolae Bacalbasa, Gabriela Ceobanu, Madalina Ilie, Valentin Enache, Gabriel Constantinescu, Simona Bungau, Camelia Cristina Diaconu
    Journal of Personalized Medicine.2021; 11(8): 694.     CrossRef
  • Controversies in EUS: Do we need miniprobes?
    Hans Seifert, Pietro Fusaroli, PaoloGiorgio Arcidiacono, Barbara Braden, Felix Herth, Michael Hocke, Alberto Larghi, Bertrand Napoleon, Mihai Rimbas, BogdanSilvio Ungureanu, Adrian Sãftoiu, AnandV Sahai, ChristophF Dietrich
    Endoscopic Ultrasound.2021; 10(4): 246.     CrossRef
  • Convolutional neural network‐based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images
    Chang Kyo Oh, Taewan Kim, Yu Kyung Cho, Dae Young Cheung, Bo‐In Lee, Young‐Seok Cho, Jin Il Kim, Myung‐Gyu Choi, Han Hee Lee, Seungchul Lee
    Journal of Gastroenterology and Hepatology.2021; 36(12): 3387.     CrossRef
  • The Value of Endoscopic Ultrasonography in the Endoscopic Resection of Gastrointestinal Stromal Tumors
    Jian-Wei Mi, Jia-Qi Wang, Jie Liu, Li-Xian Zhang, Hong-Wei Du, Dong-Qiang Zhao
    International Journal of General Medicine.2021; Volume 14: 5149.     CrossRef
  • Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor
    Jia Liu, Yuyong Tan, Deliang Liu, Chenjie Li, Meixian Le, Hejun Zhou
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Endoscopic Resection of Gastrointestinal Stromal Tumor: Is It Safe?
    Moon Kyung Joo
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 180.     CrossRef
  • Endoscopic Resection for Gastric Subepithelial Tumor with Backup Laparoscopic Surgery: Description of a Single-Center Experience
    Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Joseph Lin, Kuo-Hua Lin
    Journal of Clinical Medicine.2021; 10(19): 4423.     CrossRef
  • Successful Endoscopic Resection of a Rectal Gastrointestinal Stromal Tumor Larger Than 5 cm
    Seong Jung Kim, Yun Jung, Ran Hong, Jun Lee
    The Korean Journal of Gastroenterology.2021; 78(4): 235.     CrossRef
  • A Nomogram for Predicting Laparoscopic and Endoscopic Cooperative Surgery during the Endoscopic Resection of Subepithelial Tumors of the Upper Gastrointestinal Tract
    Shun-Wen Hsiao, Mei-Wen Chen, Chia-Wei Yang, Kuo-Hua Lin, Yang-Yuan Chen, Chew-Teng Kor, Siou-Ping Huang, Hsu-Heng Yen
    Diagnostics.2021; 11(11): 2160.     CrossRef
  • Building Radiomics Models Based on Triple-Phase CT Images Combining Clinical Features for Discriminating the Risk Rating in Gastrointestinal Stromal Tumors
    Meihua Shao, Zhongfeng Niu, Linyang He, Zhaoxing Fang, Jie He, Zongyu Xie, Guohua Cheng, Jian Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastrointestinal stromal tumor of the rectum resected by transanal total mesorectal excision after neoadjuvant imatinib treatment: A case report
    Takuya Yano, Masahiro Nakahara, Hiroshi Okuda, Toshihiko Nishidate, Ichiro Takemasa, Masahiko Fujimori, Hirofumi Nakatsuka, Hironobu Amano, Hideki Ohdan, Toshio Noriyuki
    Asian Journal of Endoscopic Surgery.2020; 13(4): 574.     CrossRef
  • Wedge gastrectomy: Robot-assisted with a hand-sewn repair versus a laparoscopic linear stapler technique for gastric subepithelial tumors
    Chairat Supsamutchai, Thitipong Setthalikhit, Chumpon Wilasrusmee, Pornraksa Ovartchaiyapong, Jakrapan Jirasiritham, Pattawia Choikrua, Pitichote Hiranyatheb
    Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(1): 17.     CrossRef
  • Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
    Heejung Chae, Min-Hee Ryu, Jungeun Ma, Moyeol Beck, Yoon-Koo Kang
    Investigational New Drugs.2020; 38(2): 493.     CrossRef
  • Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors
    Jian Wang, Yuan Yin, Chaoyong Shen, Xiaonan Yin, Zhaolun Cai, Lin Pu, Wei Fu, Yaxuan Wang, Bo Zhang
    Medicine.2020; 99(9): e19275.     CrossRef
  • Multiple Intra-abdominal Leiomyosarcoma in a Single Patient
    Rajshekhar C. Jaka, N. Chandra Mouli, T. Ravi Kumar, Akshay V. Gokak
    Indian Journal of Surgical Oncology.2020; 11(S1): 63.     CrossRef
  • Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors
    Caiyue Ren, Shengping Wang, Shengjian Zhang
    Cancer Imaging.2020;[Epub]     CrossRef
  • Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research


    Fangxing Peng, Yao Liu
    Cancer Management and Research.2020; Volume 12: 3877.     CrossRef
  • Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: A preliminary meta‐analysis
    Hanlong Zhu, Si Zhao, Ruonan Jiao, Jian Zhou, Chunmei Zhang, Lin Miao
    Journal of Gastroenterology and Hepatology.2020; 35(11): 1858.     CrossRef
  • Laparoscopy‑assisted endoscopic full‑thickness resection of upper gastrointestinal subepithelial tumors: A single‑center early experience
    Prasit Mahawongkajit, Pakkavuth Chanswangphuvana
    Molecular and Clinical Oncology.2020;[Epub]     CrossRef
  • Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review


    Peng Liu, Fengbo Tan, Heli Liu, Jie Ge, Sheng Liu, Tianxiang Lei, Xianhui Zhao
    Cancer Management and Research.2020; Volume 12: 7681.     CrossRef
  • Laparoscopic Transabdominal Dissection and Transection of the Distal Rectum Followed by Local Excision Through the Anus for Rectal Gastrointestinal Stromal Tumor
    Shin Emoto, Takashi Akiyoshi, Koji Fukata, Toshiya Nagasaki, Yosuke Fukunaga
    Diseases of the Colon & Rectum.2020; 63(11): e542.     CrossRef
  • Laparoscopic resectional oesophago-gastroplasty: a novel technique for minimally invasive treatment of large high gastric lesser curve GIST involving gastroesophageal junction
    Mang Yik Foo, Baldwin P M Yeung, Jeremy T H Tan
    Journal of Surgical Case Reports.2020;[Epub]     CrossRef
  • Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map
    Chen Li, Ke-Lu Yang, Quan Wang, Jin-Hui Tian, Yang Li, Zhi-Dong Gao, Xiao-Dong Yang, Ying-Jiang Ye, Ke-Wei Jiang
    World Journal of Gastroenterology.2020; 26(47): 7550.     CrossRef
  • Application of NOTES combined with ESD for the treatment of an exogenous gastric stromal tumor: A case report and review of the literature
    Xiao-Bo Liu, Zi-Ye Gao, Sandeep Pandey, Bao-Zhen Shan, Ping Liu, Chuan-Tao Sun, Sheng-Bao Li, Shu Jin
    World Academy of Sciences Journal.2020;[Epub]     CrossRef
  • Laparoscopic versus open resection of gastrointestinal stromal tumors: survival outcomes from the NCDB
    Colette S. Inaba, Austin Dosch, Christina Y. Koh, Sarath Sujatha-Bhaskar, Marija Pejcinovska, Brian R. Smith, Ninh T. Nguyen
    Surgical Endoscopy.2019; 33(3): 923.     CrossRef
  • Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method
    Ming Liu, Liheng Liu, Erhu Jin
    Gastric Cancer.2019; 22(4): 769.     CrossRef
  • Per oral endoscopic tumor (POET) resection for treatment of upper gastrointestinal subepithelial tumors
    Philip Wai Yan Chiu, Hon Chi Yip, Anthony Yuen Bun Teoh, Vivien Wai Yin Wong, Shannon Melissa Chan, Simon Kin Hung Wong, Enders Kwok Wai Ng
    Surgical Endoscopy.2019; 33(4): 1326.     CrossRef
  • Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
    Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang
    Cancer Medicine.2019; 8(3): 1034.     CrossRef
  • PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY
    João Bernardo Sancio Rocha RODRIGUES, Renato Gomes CAMPANATI, Francisco NOLASCO, Athos Miranda BERNARDES, Soraya Rodrigues de Almeida SANCHES, Paulo Roberto SAVASSI-ROCHA
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2019;[Epub]     CrossRef
  • Value of contrast‐enhanced harmonic endoscopic ultrasonography in differentiating between gastrointestinal stromal tumors: A meta‐analysis
    Jia Yue Tang, Ke Gong Tao, Li Yuan Zhang, Kai Ming Wu, Jian Shi, Xin Zeng, Yong Lin
    Journal of Digestive Diseases.2019; 20(3): 127.     CrossRef
  • Future of full thickness resection – Devices, indications, robotics, what is missing
    Philip WY Chiu
    Techniques in Gastrointestinal Endoscopy.2019; 21(1): 48.     CrossRef
  • Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs)
    Mincong Wang, Anwei Xue, Wei Yuan, Xiaodong Gao, Min Fu, Yong Fang, Li Wang, Ping Shu, He Li, Yingyong Hou, Kuntang Shen, Yinghong Sun, Xinyu Qin
    Journal of Gastrointestinal Surgery.2019; 23(11): 2136.     CrossRef
  • Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors —8 cases: A case report
    Jwa Hoon Kim, Min-Hee Ryu, Young Soo Park, Hyun Jin Kim, Hyojung Park, Yoon-Koo Kang
    World Journal of Gastroenterology.2019; 25(16): 2010.     CrossRef
  • Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion
    Liangliang Xu, Ming Zhang, Mingqing Xu
    Medicine.2019; 98(20): e15482.     CrossRef
  • Endoscopic full-thickness resection for a gastrointestinal stromal tumor in a liver transplant recipient
    Man Xie, Wei Rao, Peng Zhang, Qingxi Zhao, Zibin Tian
    Medicine.2019; 98(31): e16669.     CrossRef
  • Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients
    Hanmei Chen, Jing Liu, Yuhong Zhou, Yingyong Hou, Guo Ma, Weimin Cai
    Therapeutic Drug Monitoring.2019; 41(5): 582.     CrossRef
  • Value of CT-Based Texture Analysis in Preoperative Prediction of the Grade of Gastrointestinal Stromal Tumors Compared to Conventional CT Imaging
    Caiyue Ren, Shengping Wang, Shengjian Zhang, Zhaoxia Jiang
    Iranian Journal of Radiology.2019;[Epub]     CrossRef
  • Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
    Fousséni Alassani, Boyodi Tchangai, Aklesso Bagny, Ablavi A. Adani-Ife, Kossigan A. Amavi, Tchin Darre, Komla Attipou
    Oncology and Therapy.2019; 7(2): 159.     CrossRef
  • Clinical Relevance of the Location of Gastric Gastrointestinal Stromal Tumors
    Eun Jeong Gong
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2019; 19(3): 143.     CrossRef
  • Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Hyungwoo Cho, Min-Hee Ryu, Yongjune Lee, Young Soo Park, Ki-Hun Kim, Jwa Hoon Kim, Yangsoon Park, Sun Mi Lee, Chan Wook Kim, Beom Soo Kim, Moon-Won Yoo, Yoon-Koo Kang
    The Oncologist.2019; 24(12): e1443.     CrossRef
  • Gastrointestinal stromal tumors: Do we follow the current guidelines? A self-critique
    MohammadEzzedien Rabie, Abdelelah Hummadi, Mohammad Bazeed, Ismail El Hakeem, AbdullaSaad Al Qahtani, Hesham Haroon, Abbas Al Zain
    Saudi Surgical Journal.2019; 7(3): 100.     CrossRef
  • Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
    Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
    The Oncologist.2019; 24(11): e1212.     CrossRef
  • The fourth space surgery: endoscopic subserosal dissection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer
    Fei Liu, Song Zhang, Wei Ren, Tian Yang, Ying Lv, Tingsheng Ling, Xiaoping Zou, Lei Wang
    Surgical Endoscopy.2018; 32(5): 2575.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • Subepitheliale Raumforderungen
    N. Glaser, R. Thimme, A. Schmidt
    Der Gastroenterologe.2018; 13(2): 113.     CrossRef
  • Tyrosine kinase inhibitor therapies for gastrointestinal stromal tumours
    Simone Mocellin, Sandro Pasquali, Luca Campana, Yuhong Yuan, Alessandro Gronchi, Ewen Griffiths, Ravinder Vohra
    Cochrane Database of Systematic Reviews.2018;[Epub]     CrossRef
  • Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib
    Jianwei Tang, Rui Zhao, Xiaobo Zheng, Liangliang Xu, Yong Wang, Lei Feng, Shengsheng Ren, Peng Wang, Ming Zhang, Mingqing Xu
    Medicine.2018; 97(29): e11400.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Inhibition of stromal‐interacting molecule 1‐mediated store‐operated Ca2+ entry as a novel strategy for the treatment of acquired imatinib‐resistant gastrointestinal stromal tumors
    Ziyi Yang, Lijia Pan, Shilei Liu, Fengnan Li, Wenjie Lv, Yijun Shu, Ping Dong
    Cancer Science.2018; 109(9): 2792.     CrossRef
  • Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe
    Lin Tu, Peter Hohenberger, Heike Allgayer, Hui Cao
    Visceral Medicine.2018; 34(5): 353.     CrossRef
  • Gastric ectopic pancreas mimicking a gastrointestinal stromal tumour: A case report
    Zdravko Štor, Jurij Hanžel
    International Journal of Surgery Case Reports.2018; 53: 348.     CrossRef
  • Tumor rupture of gastric gastrointestinal stromal tumors during endoscopic resection: a risk factor for peritoneal metastasis?
    Shiyi Song, Wei Ren, Yi Wang, Shu Zhang, Song Zhang, Fei Liu, Qiang Cai, Guifang Xu, Xiaoping Zou, Lei Wang
    Endoscopy International Open.2018; 06(08): E950.     CrossRef
  • Drill needle aspiration biopsy for submucosal tumors in an experimental study
    Masaya Uesato, Tomohide Tamachi, Naoyuki Hanari, Yorihiko Muto, Akiko Kagaya, Ryuma Urahama, Yukiko Ogura, Hiroshi Suito, Akira Nakano, Mizuho Aikawa, Takashi Oide, Hisahiro Matsubara
    Gastric Cancer.2017; 20(3): 475.     CrossRef
  • Tumor del estroma extragastrointestinal primario hepático gigante
    Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
    Cirugía Española.2017; 95(9): 547.     CrossRef
  • Cancer biology of small gastrointestinal stromal tumors (<2 cm): What is the risk of malignancy?
    K. Søreide
    European Journal of Surgical Oncology (EJSO).2017; 43(7): 1344.     CrossRef
  • An unexpected cause of gastric submucosal lesion
    Rachid Guimarães Nagem
    Einstein (São Paulo).2017; 15(1): 112.     CrossRef
  • Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)
    Mónica Ballesteros, Nadia Montero, Antonio López-Pousa, Gerard Urrútia, Ivan Solà, Gabriel Rada, Hector Pardo-Hernandez, Xavier Bonfill
    BMC Medical Research Methodology.2017;[Epub]     CrossRef
  • Laparoscopic management of gastric gastrointestinal stromal tumors: A retrospective 10-year single-center experience
    Guan-Qun Liao, Tao Chen, Xiao-Long Qi, Yan-Feng Hu, Hao Liu, Jiang Yu, Guo-Xin Li
    World Journal of Gastroenterology.2017; 23(19): 3522.     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16 Ink4A /p14 ARF gene expressions: An in vivo and in vitro study
    Jiang-Li Wang, Jiang-Hong Wu, Cai Hong, Ya-Nong Wang, Ye Zhou, Zi-Wen Long, Ying Zhou, Hai-Shu Qin
    Pathology - Research and Practice.2017; 213(12): 1542.     CrossRef
  • Giant Primary Extra Gastrointestinal Stromal Tumor of the Liver
    Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
    Cirugía Española (English Edition).2017; 95(9): 547.     CrossRef
  • Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Rui Zhao, Yong Wang, Yuqian Huang, Yaping Cui, Lin Xia, Yi Chen, Wen Zhuang, Yong Zhou, Xiaoting Wu
    Scientific Reports.2017;[Epub]     CrossRef
  • 25,759 View
  • 1,149 Download
  • 147 Web of Science
  • 132 Crossref
Close layer
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
Cancer Res Treat. 2016;48(2):546-552.   Published online June 22, 2015
DOI: https://doi.org/10.4143/crt.2015.015
AbstractAbstract PDFPubReaderePub
Purpose
The incidence of gastrointestinal stromal tumors (GISTs) harboring platelet-derived growth factor receptor alpha (PDGFRA) mutations is low, therefore further investigation of the efficacy of imatinib in this subgroup was needed.
Materials and Methods
Patients with PDGFRA-mutant GISTs who received imatinib as primary therapy for advanced disease between January 2000 and June 2012 were identified from the GIST registry of Asan Medical Center, Seoul, Korea.
Results
KIT and PDGFRA genotyping in 823 patients identified 18 patients (2%) with PDGFRA mutations who were treated with first-line imatinib. Exon 18 D842V substitution, non-D842V exon 18 mutations, and exon 12 mutations were detected in nine (50%), four (22%), and five (28%) patients, respectively. Objective response rate differed significantly between patients with the D842V mutation and those with non-D842V mutations (0% [0/5] vs. 71% [5/7], p=0.03). In all patients, median progression-free survival (PFS) and overall survival (OS) was 24.8 months (95% confidence interval [CI], 0.0 to 57.2) and 51.2 months (95% CI, 37.1 to 65.3), respectively. Significantly, poorer PFS was observed for patients with D842V-mutant GISTs than those with non-D842V PDGFRA-mutant GISTs: median 3.8 months (95% CI, 1.4 to 6.3) versus 29.5 months (95% CI, 18.3 to 40.7) (p < 0.001). Patients with the D842V mutation had poorer OS than those with non-D842V PDGFRA mutations: median 25.2 months (95% CI, 12.7 to 37.8) versus 59.8 months (95% CI, 43.0 to 76.5) (p=0.02).
Conclusion
Imatinib is active against non-D842V PDGFRA-mutant GISTs, whereas GISTs harboring the D842V mutation are primarily resistant to imatinib.

Citations

Citations to this article as recorded by  
  • Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
    Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil
    Nature Medicine.2024; 30(2): 498.     CrossRef
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
    Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
    International Journal of Clinical Oncology.2024; 29(6): 647.     CrossRef
  • Establishing biomarkers for soft tissue sarcomas
    Anna M. Czarnecka, Paulina Chmiel, Piotr Błoński, Piotr Rutkowski
    Expert Review of Anticancer Therapy.2024; 24(6): 407.     CrossRef
  • First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor
    Rebecca Ganzon, Wei Chen, Gabriel Tinoco, Jose I. Mayordomo
    Case Reports in Oncological Medicine.2024;[Epub]     CrossRef
  • Therapeutic advances of targeting receptor tyrosine kinases in cancer
    Ciprian Tomuleasa, Adrian-Bogdan Tigu, Raluca Munteanu, Cristian-Silviu Moldovan, David Kegyes, Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Imatinib adherence prediction using machine learning approach in patients with gastrointestinal stromal tumor
    Li Liu, Ze Yu, Hefen Chen, Zhujun Gong, Xiao Huang, Linhua Chen, Ziying Fan, Jinyuan Zhang, Jiannan Yan, Hongkun Tian, Xiangyu Zeng, Zhiliang Chen, Peng Zhang, Hong Zhou
    Cancer.2024;[Epub]     CrossRef
  • Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update
    Chunxiao He, Zilong Wang, Jiaying Yu, Shuang Mao, Xi Xiang
    Current Treatment Options in Oncology.2024; 25(11): 1390.     CrossRef
  • Personalized and targeted therapies
    Magdalena Wiśniewska, Michał Wiśniewski, Marzena A. Lewandowska
    Physical Sciences Reviews.2023; 8(9): 2103.     CrossRef
  • Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
    Mojca Unk, Barbara Jezeršek Novaković, Srdjan Novaković
    Cancers.2023; 15(5): 1498.     CrossRef
  • Precision Oncology in Gastrointestinal Stromal Tumors
    Hiba Mechahougui, Montemurro Michael, Alex Friedlaender
    Current Oncology.2023; 30(5): 4648.     CrossRef
  • Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor
    Vinayak Venkataraman, Suzanne George, Gregory M Cote
    The Oncologist.2023; 28(8): 671.     CrossRef
  • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
    Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
    Cancers.2023; 15(16): 4081.     CrossRef
  • Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients
    Stijn J. C. van der Burg, Deborah van de Wal, Evelyne Roets, Neeltje Steeghs, Johanna W. van Sandick, Martijn Kerst, Frits van Coevorden, Koen J. Hartemink, Xander A. A. F. A. Veenhof, Anne Miek Koenen, Nikki Ijzerman, Winette T. A. van der Graaf, Yvonne
    Annals of Surgical Oncology.2023; 30(13): 8660.     CrossRef
  • New treatment strategies for advanced-stage gastrointestinal stromal tumours
    Lillian R. Klug, Homma M. Khosroyani, Jason D. Kent, Michael C. Heinrich
    Nature Reviews Clinical Oncology.2022; 19(5): 328.     CrossRef
  • Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China
    Peng Zhang, Ming Wang, Jian Li, Xiaodong Gao, Bo Zhang, Han Liang, Ye Zhou, Guoqing Liao, Fan Feng, Yanbing Zhou, Jiren Yu, Jun Zhang, Yongjian Zhou, Yingjiang Ye, Jiansi Chen, Qun Zhao, Kuntang Shen, Hui Cao, Kaixiong Tao
    Advances in Therapy.2022; 39(6): 2920.     CrossRef
  • ACR Appropriateness Criteria® Staging of Colorectal Cancer: 2021 Update
    Elena K. Korngold, Courtney Moreno, David H. Kim, Kathryn J. Fowler, Brooks D. Cash, Kevin J. Chang, Kenneth L. Gage, Aakash H. Gajjar, Evelyn M. Garcia, Avinash R. Kambadakone, Peter S. Liu, Meghan Macomber, Daniele Marin, Jason A. Pietryga, Cynthia S. S
    Journal of the American College of Radiology.2022; 19(5): S208.     CrossRef
  • Gastrointestinal stromal tumors caused by novel germline variants in SDHB and KIT: a report of two cases and literature review
    Sean Rasmussen, Ashley Stueck, Bruce Colwell, Daniel Gaston, Michael Carter
    Clinical Journal of Gastroenterology.2022; 15(5): 869.     CrossRef
  • An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
    Yingchao Sun, Lei Yue, Pengfu Xu, Weiling Hu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib
    Newton A.C.S. Wong, Christel Garcia-Petit, Adam Dangoor, Nicola Andrew
    Cancer Genetics.2022; 268-269: 46.     CrossRef
  • Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report
    Mojca Unk, Alenka Bombač, Barbara Jezeršek Novaković, Vida Stegel, Vita Šetrajčič, Olga Blatnik, Gašper Klančar, Srdjan Novaković
    Oncology Reports.2022;[Epub]     CrossRef
  • Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
    Cissimol P. Joseph, Sarah N. Abaricia, Michelle A. Angelis, Kathleen Polson, Robin L. Jones, Yoon-Koo Kang, Richard F. Riedel, Patrick Schöffski, César Serrano, Jonathan Trent, Eric D. Tetzlaff, Tuan Dong Si, Teresa Zhou, Ashley Doyle, Sebastian Bauer, Ma
    The Oncologist.2021; 26(4): e622.     CrossRef
  • Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
    Robin L. Jones, César Serrano, Margaret von Mehren, Suzanne George, Michael C. Heinrich, Yoon-Koo Kang, Patrick Schöffski, Philippe A. Cassier, Olivier Mir, Sant P. Chawla, Ferry A.L.M. Eskens, Piotr Rutkowski, William D. Tap, Teresa Zhou, Maria Roche, Se
    European Journal of Cancer.2021; 145: 132.     CrossRef
  • Prognostic and predictive values of the KIT11-mutated grading system in patients with gastrointestinal stromal tumors: a retrospective study
    Ling-Jun Song, Hui-Juan Ge, Xiao-Qin Shi, Wei-Wei Shen
    Human Pathology.2021; 110: 31.     CrossRef
  • The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
    Alessandro Rizzo, Maria Abbondanza Pantaleo, Annalisa Astolfi, Valentina Indio, Margherita Nannini
    Cancers.2021; 13(4): 705.     CrossRef
  • Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
    Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George
    BMC Cancer.2021;[Epub]     CrossRef
  • Stellungnahme der AIO, DGHO und DGVS zur Nutzenbewertung von Avapritinib bei gastrointestinalen Stromatumoren (GIST)

    Zeitschrift für Gastroenterologie.2021; 59(04): 366.     CrossRef
  • Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice
    Elisabeth M. P. Steeghs, Hans Gelderblom, Vincent K. Y. Ho, Quirinus J. M. Voorham, Stefan M. Willems, Katrien Grünberg, Marjolijn J. L. Ligtenberg
    Gastric Cancer.2021; 24(5): 990.     CrossRef
  • New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications
    Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza
    Bioorganic & Medicinal Chemistry.2021; 46: 116340.     CrossRef
  • Avapritinib in Advanced Gastrointestinal Stromal Tumor: Case Series and Review of the Literature From a Tertiary Care Center in India
    Saurav Verma, Rohit Reddy, Sheragaru Hanumanthappa Chandrashekhara, Shamim Ahmed Shamim, Sarthak Tripathy, Sameer Rastogi
    Future Science OA.2021;[Epub]     CrossRef
  • Mutations of the c-Kit and PDGFRA Gene in Gastrointestinal Stromal Tumors among Hakka Population of Southern China
    S Wang, Q Zhang, H Wu, Z Yang, X Guo, F Wang, Z Yu, Z Zhong
    Nigerian Journal of Clinical Practice.2021; 24(6): 814.     CrossRef
  • Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation
    Valentina Indio, Gloria Ravegnini, Annalisa Astolfi, Milena Urbini, Maristella Saponara, Antonio De Leo, Elisa Gruppioni, Giuseppe Tarantino, Sabrina Angelini, Andrea Pession, Maria Abbondanza Pantaleo, Margherita Nannini
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
    Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap, Piotr Rutkowski, Sant P Chawla, Jonathan Trent, Meera Tugnait, Erica K Evans, Tamieka La
    The Lancet Oncology.2020; 21(7): 935.     CrossRef
  • Adult Jejuno-Jejunal Intussusceptions due to Gastrointestinal Stromal Tumor
    Jayabal Pandiaraja
    Indian Journal of Medical and Paediatric Oncology.2020; 41(04): 602.     CrossRef
  • Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib
    Margherita Nannini, Giuseppe Tarantino, Valentina Indio, Gloria Ravegnini, Annalisa Astolfi, Milena Urbini, Antonio De Leo, Donatella Santini, Claudio Ceccarelli, Elisa Gruppioni, Annalisa Altimari, Paolo Castellucci, Stefano Fanti, Valerio Di Scioscio, M
    Scientific Reports.2019;[Epub]     CrossRef
  • Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal
    Alexander Baraniskin, Jean-Luc Van Laethem, Lucjan Wyrwicz, Ulrich Guller, Harpreet S. Wasan, Tamara Matysiak-Budnik, Thomas Gruenberger, Michel Ducreux, Fatima Carneiro, Eric Van Cutsem, Thomas Seufferlein, Wolff Schmiegel
    European Journal of Cancer.2017; 86: 305.     CrossRef
  • A precision therapy against cancers driven by KIT/PDGFRA mutations
    Erica K. Evans, Alexandra K. Gardino, Joseph L. Kim, Brian L. Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson, Lucian DiPietro, Yulian Zhang, Natasja Brooijmans, Timothy P. LaBranche, Agnieszka Wozniak, Y
    Science Translational Medicine.2017;[Epub]     CrossRef
  • Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature
    Pieter A. Boonstra, Jourik A. Gietema, Albert J.H. Suurmeijer, Matthew R. Groves, Fernando de Assis Batista, Ed Schuuring, Anna K.L. Reyners
    Oncotarget.2017; 8(65): 109836.     CrossRef
  • Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments
    Michael Pogorzelski, Johanna Falkenhorst, Sebastian Bauer
    Current Opinion in Oncology.2016; 28(4): 331.     CrossRef
  • 12,012 View
  • 209 Download
  • 41 Web of Science
  • 38 Crossref
Close layer
Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
Cancer Res Treat. 2016;48(1):162-170.   Published online September 1, 2015
DOI: https://doi.org/10.4143/crt.2015.017
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the incidence of imatinib-associated skin rash, the interventional outcomes of severe rash, and impact of severe rash on the outcomes of imatinib treatment in gastrointestinal stromal tumor (GIST) patients.
Materials and Methods
A total of 620 patients were administered adjuvant or palliative imatinib for GIST at Asan Medical Center between January 2000 and July 2012. This analysis focused on a group of 42 patients who developed a severe rash requiring major interventions, defined as dose interruption or reduction of imatinib or systemic steroid use.
Results
Of the 620 patients treated with imatinib, 148 patients (23.9%) developed an imatinibassociated skin rash; 42 patients (6.8%) developed a severe rash requiring major intervention. Of these, 28 patients (66.8%) successfully continued imatinib with interventions. Serial blood eosinophil levels during imatinib treatment were associated with skin rash and severity. A significant association was observed between successful intervention and blood eosinophil level at the time of intervention initiation. In metastatic settings, patients with severe rash requiring major interventions tended to show poorer progression-free survival than patients who did not require major intervention and patients with no rash, although this finding was not statistically significant (p=0.326).
Conclusion
By aggressive treatment of severe rash through modification of imatinib dose or use of systemic steroid, the majority of patients can continue on imatinib. In particular, imatinib dose intensity can be maintained with use of systemic steroid. Measuring the blood eosinophil levels may be helpful in guiding the management plan for skin rash regarding the intensity and duration of interventions.

Citations

Citations to this article as recorded by  
  • Lichenoid and psoriasiform drug induced rush during imatinib therapy: a clinical case
    Albina N. Khlebnikova, Valentina E. Shikina, Gayane E. Bagramova
    Almanac of Clinical Medicine.2024; 51(7): 417.     CrossRef
  • Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor
    Xiao Huang, Linhua Chen, Li Liu, Hefen Chen, Zhujun Gong, Jianbo Lyu, Yao Li, Qi Jiang, Xiangyu Zeng, Peng Zhang, Hong Zhou
    International Immunopharmacology.2024; 140: 112728.     CrossRef
  • Assessment of Skin Toxicity in an in Vitro Reconstituted Human Epidermis Model Using Deep Learning
    Fangyao Hu, Sara F. Santagostino, Dimitry M. Danilenko, Min Tseng, Jochen Brumm, Philip Zehnder, Kai Connie Wu
    The American Journal of Pathology.2022; 192(4): 687.     CrossRef
  • Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
    Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson
    Cancers.2022; 14(7): 1832.     CrossRef
  • Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
    Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
    International Journal of Cancer.2022; 151(10): 1770.     CrossRef
  • Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors
    Jiangxia Du, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He, Xiaohong Wang, Peihua Luo
    Expert Opinion on Drug Metabolism & Toxicology.2021; 17(11): 1311.     CrossRef
  • Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors
    E. A. Shatokhina, A. G. Turkina, L. S. Kruglova
    Russian journal of hematology and transfusiology.2020; 65(2): 154.     CrossRef
  • Experience in Using Jumihaidokuto and Orengedokuto for Skin Disorders Caused by Molecular Target Drugs
    Koki MORI, Tatsuya HIROSE, Koji TANAKA, Atsuko TAKEDA, Masahiro UNO, Hajime TAKAGI
    Kampo Medicine.2020; 71(1): 30.     CrossRef
  • Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study
    Eo Jin Kim, Min-Hee Ryu, Sook Ryun Park, Mo Youl Beck, Woo Jin Lee, Mi Woo Lee, Yoon-Koo Kang
    The Oncologist.2020; 25(11): e1785.     CrossRef
  • Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist
    Antonio Martinez-Lopez, Carlos Cuenca-Barrales, Trinidad Montero-Vilchez, Alejandro Molina-Leyva, Salvador Arias-Santiago
    Journal of the American Academy of Dermatology.2020; 83(6): 1738.     CrossRef
  • Cystic acne due to imatinib therapy for chronic myelocytic leukemia
    Andrew Hwang, Andrew Iskandar, Michael del Rosario, Constantin A Dasanu
    Journal of Oncology Pharmacy Practice.2019; 25(4): 972.     CrossRef
  • Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
    Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang
    Cancer Medicine.2019; 8(3): 1034.     CrossRef
  • A successful approach to overcome imatinib-induced skin toxicity in a GIST patient
    Ingrid M.E. Desar, Carla M.L. van Herpen, Nielka P. van Erp, Suzanne E.J. Kaal, Peter C.M. van de Kerkhof, Winette T.A. van der Graaf
    Anti-Cancer Drugs.2016; 27(6): 576.     CrossRef
  • 11,282 View
  • 151 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2012;44(2):85-96.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.85
AbstractAbstract PDFPubReaderePub
Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.

Citations

Citations to this article as recorded by  
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video)
    Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors
    Joonhong Park, Hae Jung Sul, Jeong Goo Kim
    Medicina.2021; 57(2): 174.     CrossRef
  • The Pathologic Confirmation in Subepithelial Tumors
    Kwan Hong Lee, Chan Kyoo Yoo, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, Oh Young Lee, Dong Soo Han, Byung Chul Yoon, Ho Soon Choi, Jai Hoon Yoon
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 215.     CrossRef
  • Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
    Haojie Du, Longgui Ning, Sha Li, Xinhe Lou, Hongtan Chen, Fengling Hu, Guodong Shan, Fenming Zhang, Guoqiang Xu
    Clinical and Translational Gastroenterology.2020; 11(3): e00156.     CrossRef
  • Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schӧffski
    British Journal of Cancer.2020; 122(8): 1158.     CrossRef
  • Life-threatening bleeding with intussusception due to gastrointestinal stromal tumor: a case report
    Min Sung Kim, In Teak Woo, Young Min Jo, Jin Hyung Lee, Byung Sam Park
    Surgical Case Reports.2019;[Epub]     CrossRef
  • Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: Single center experience
    Cristina Maggioni, Atsuo Shida, Raffaello Mancini, Luigi Ioni, Graziano Pernazza
    The International Journal of Medical Robotics and Computer Assisted Surgery.2019;[Epub]     CrossRef
  • A novel technique for removing large gastric subepithelial tumors with ESD method in the subcardia region
    Bingtuan Liu, Han Chen, Weifeng Zhang, Guoxin Zhang
    Oncology Letters.2019;[Epub]     CrossRef
  • Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors
    In Sun Yoon, Ji Hoon Shin, Kichang Han, Pyo Nyun Kim, Ki Hun Kim, Yoon-Koo Kang, Heung Kyu Ko
    Korean Journal of Radiology.2018; 19(1): 54.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Toni
    Therapeutic Advances in Medical Oncology.2018;[Epub]     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Extra-gastrointestinal stromal tumor of the pancreas: report of a case
    Hyung Jun Kwon
    Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(4): 237.     CrossRef
  • The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    Toshirou Nishida, Jean-Yves Blay, Seiichi Hirota, Yuko Kitagawa, Yoon-Koo Kang
    Gastric Cancer.2016; 19(1): 3.     CrossRef
  • Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
    Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(1): 162.     CrossRef
  • Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
    Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(2): 546.     CrossRef
  • Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)
    Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, Baek-Yeol Ryoo, George D. Demetri, Yoon-Koo Kang
    European Journal of Cancer.2016; 52: 201.     CrossRef
  • Schwannoma of the stomach: a case report
    Aminder Singh, Ankur Mittal, Bhavna Garg, Neena Sood
    Journal of Medical Case Reports.2016;[Epub]     CrossRef
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Unusual gastroduodenal intussusception secondary to a gastrointestinal stromal tumor of the gastric fundus
    Toshihide Komatsubara, Toru Zuiki, Alan Kawarai Lefor, Norio Hirota, Jun Oki
    International Journal of Surgery Open.2016; 5: 33.     CrossRef
  • Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial
    Changhoon Yoo, Yoon-Koo Kang
    Clinical Investigation.2015; 5(7): 665.     CrossRef
  • The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Seong Joon Park, Min-Hee Ryu, Baek-Yeol Ryoo, Young Soo Park, Byeong Seok Sohn, Hwa Jung Kim, Chan Wook Kim, Ki-Hun Kim, Chang Sik Yu, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang
    Annals of Surgical Oncology.2014; 21(13): 4211.     CrossRef
  • Minimally invasive surgery for submucosal (subepithelial) tumors of the stomach
    Chang Min Lee
    World Journal of Gastroenterology.2014; 20(36): 13035.     CrossRef
  • Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu, M-H Ryu
    British Journal of Cancer.2013; 109(9): 2309.     CrossRef
  • Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri
    The Lancet Oncology.2013; 14(12): 1175.     CrossRef
  • Surgeon's role for gastric gastrointestinal stromal tumor in imatinib era
    Ji Yeon Park, Young-Woo Kim
    Korean Journal of Clinical Oncology.2013; 9(1): 5.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
    Seong-Ho Kong, Han-Kwang Yang
    Journal of Gastric Cancer.2013; 13(1): 3.     CrossRef
  • Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
    Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 51,173 View
  • 133 Download
  • 32 Crossref
Close layer
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
Ji Seon Oh, Jae-Lyun Lee, Mi-Jung Kim, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
Cancer Res Treat. 2006;38(3):178-183.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.178
AbstractAbstract PDFPubReaderePub

Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST.

Citations

Citations to this article as recorded by  
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
    Ki Choon Sim, Beom Jin Park, Na Yeon Han, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Hyun Kwon Ha, Hyoung Rae Kim
    Journal of the Korean Society of Radiology.2014; 71(5): 239.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Cancer Research and Treatment.2012; 44(2): 85.     CrossRef
  • Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
    Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
    Journal of the Korean Society of Coloproctology.2011; 27(3): 147.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Hye Jin Kang, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Journal of Korean Medical Science.2010; 25(11): 1543.     CrossRef
  • Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang
    Journal of the Korean Medical Association.2007; 50(9): 830.     CrossRef
  • 11,099 View
  • 86 Download
  • 7 Crossref
Close layer
Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy
Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Jung Shin Lee, Yoon-Koo Kang
Cancer Res Treat. 2005;37(4):201-207.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.201
AbstractAbstract PDFPubReaderePub
Purpose

Fluoropyrimidine (F) and platinum (P) combination chemotherapy has been widely used for the first line treatment of advanced gastric cancer (AGC). Docetaxel (D) has shown promising activity in this disease. The present study retrospectively investigated the efficacy of D monotherapy as salvage chemotherapy for AGC that is failing F and P combination chemotherapy.

Materials and Methods

A total of 34 patients, fitting the eligibility criteria, were included in this study. D was administered at a dose of 75 mg/m2 IV every 3 weeks, with dexamethasone prophylaxis. Twenty-nine patients had measurable lesions. The median treatment-free interval was 38.5 days, and 91.2% of patients had progressed within 4 months of withdrawal of the first line chemotherapy.

Results

A total of 133 cycles of D were administered, with a median of 3.5 (1~8) cycles. From an intention-to-treat analysis, 6 patients achieved partial responses (PR), with a response rate of 20.7% (95% CI, 6.0~35.4). The duration of objective PRs in these six were 2.3+, 2.5+, 2.9, 3.0+, 6.2 and 6.8 months, respectively. Six patients showed a stable disease, but 15 showed progression. The median time to progression was 4.2 months (95% CI, 2.8~5.5), with a median overall survival since the start of D monotherapy of 8.4 months (95% CI, 5.5~11.3). Grade 3/4 neutropenia and febrile neutropenia occurred in 12.9% of patients and 3.1% of cycles. The incidence of grade 3 or worse non-hematological toxicities were as follows; peripheral sensory neuropathy 9.7%, asthenia 3.2% and allergic reaction 2.7%.

Conclusion

Docetaxel, 75 mg/m2, is active in AGC as second-line chemotherapy after failure of prior exposure to the F and P combination chemotherapy, with a favorable toxicity profile.

Citations

Citations to this article as recorded by  
  • Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
    Nao Tagawa, Erika Sugiyama, Masataka Tajima, Yasutsuna Sasaki, Seigo Nakamura, Hiromi Okuyama, Hisanori Shimizu, Vilasinee Hirunpanich Sato, Tadanori Sasaki, Hitoshi Sato
    Cancer Chemotherapy and Pharmacology.2017; 80(4): 841.     CrossRef
  • Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience
    Georg-Martin Haag, Leonidas Apostolidis, Dirk Jaeger
    Tumori Journal.2014; 100(3): 237.     CrossRef
  • Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, Pierre Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, Samira Ziti-Ljajic, Veronique Trillet-Lenoir
    Clinical Cancer Research.2012; 18(6): 1743.     CrossRef
  • A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
    Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Minsun Kim, Young Joo Chun, Jung Shin Lee, Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology.2008; 61(4): 631.     CrossRef
  • 9,712 View
  • 54 Download
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP